Development of treatment for Takayasu arteritis using multiomics approach through rheumatic and musculoskeletal diseases

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K16306
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54020:Connective tissue disease and allergy-related
• Research Institution: Keio University
• Principal Investigator: Matsumoto Kotaro 慶應義塾大学, 医学部(信濃町), 助教 (00815425)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: 高安動脈炎 / 巨細胞性動脈炎 / バイオマーカー / 分子的寛解

Outline of Final Research Achievements

The purpose of this project is to elucidate the significant molecule to reflect the landscape of Takayasu arteritis. We have identified the novel molecule to reflect the pathogenesis of vasculitis using multiomics analysis. We screened vasculitis-specific molecules by combining the findings from serum proteome analysis and whole blood bulk RNA sequencing. Then, we validated the results using immunohistochemical staining and spatial transcriptome analysis. The molecule we identified can distinguish vasculitis from other rheumatic and musculoskeletal diseases. The longitudinal testing of it can predict clinical response in patients with LVV, and also monitor insidious disease activity. It may have potential as a target for diagnostic or therapeutic agents.

Free Research Field

リウマチ・膠原病

Academic Significance and Societal Importance of the Research Achievements

血管炎病態の重症度と関連し、予後の層別化、再燃の予測に有用な分子を同定した。IL-6を指標としないため、IL-6阻害治療下であっても再燃に先行して病勢を反映するバイオマーカーとなり得る。さらに、これを治療標的とした新規治療が奏功すれば、高安動脈炎の根治的治療となり得る。